跳转至内容
Merck
CN

1.16884

Millipore

Fractogel EMD DMAE (M)

登录查看公司和协议定价

别名:
Fractogel® EMD DMAE (M)
UNSPSC代码:
41115711

质量水平

ligand

diethylaminoethyl

描述

weak anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)

无菌性

sterile (Caustic Stable)

产品线

Fractogel®

形式

resin

参数

170 cm/hr flow rate
8 bar max. pressure

基质活性基团

methacrylate

平均粒径

40-90 μm

容量

100 mg binding capacity (BSA/mg of resin)

转变温度

flash point 35 °C (calculated)

密度

1.430 g/cm3

堆积密度

1000 kg/m3

应用

gene therapy
recombinant protein
vaccine development

分离技术

weak anion exchange

储存温度

2-30°C

正在寻找类似产品? 访问 产品对比指南

一般描述

Weak anion exchange Fractogel® resin featuring the tentacle technology, for purification of acidic and neutral proteins and peptides from multiple sources, pDNA purification, DNA, RNA, and endotoxin removal, large viruses purification, vaccine purification, blood fractionation, and more

特点和优势

Fractogel® EMD DMAE (M) enables:
  • Excellent binding to large viruses and plasmid DNA
  • Homogenous binding with high selectivity and purity
  • Lower elution volumes for the highest purity levels
  • Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution


Due to the titration behavior, the ion exchange capacity can be used from pH 2 to pH 9.5. The separation of proteins is based on reversible electrostatic interactions between the negatively charged regions of the proteins′ surface and the support. Proteins are retained efficiently on Fractogel® EMD DEAE when the pH of the buffer is about 1 unit above their isoelectric points (pl).

The strength of the binding depends on the following:
  • the buffer system
  • pH value of the buffer which determines the surface charge of the protein
  • the degree of the ionization of the functional groups of the exchanger
  • the concentration of the counter ions
  • the charge density on the support (protein binding capacity)

包装

  • 1.16884.0100: Fractogel® EMD DMAE (M) Resin 100ml
  • 1.16884.0010: Fractogel® EMD DMAE (M) Resin 10ml
  • 1.16884.0500: Fractogel® EMD DMAE (M) Resin 500ml
  • 1.16884.5000: Fractogel® EMD DMAE (M) Resin 5L

Plastic bottle

分析说明

Appearance: Milky, turbid suspension,free from impurities (foreign particles)
Microscopic evaluation: Uniform spherical particles,no agglomerates, no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 80 - 120 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin

法律信息

FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Flame

警示用语:

Warning

危险声明

危险分类

Flam. Liq. 3

储存分类代码

3 - Flammable liquids

WGK

WGK 3

闪点(°F)

95.0 °F

闪点(°C)

35 °C


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

商品

See case study examples of how to optimize chromatographic purification of plasmid DNA for Biopharmaceutical Applications.

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

查看所有结果

相关内容

可使用相对模式化的工艺生产活载体疫苗。但挑战依然存在,包括由于无菌过滤、载体聚集和扩大化贴壁培养而导致的产量损失。了解有关该核心平台技术的所有信息,以及如何利用合作增强的专业知识克服生产难题。

A templated process produces live vector vaccines. Challenges: yield loss, filtration, aggregation, scaling. Collaboration overcomes manufacturing hurdles.

Tailored viral vaccine manufacturing addresses virus-specific challenges through collaboration.

病毒疫苗的生产较为复杂,且并无模式化的生产方法。每一道工艺都必须根据病毒的形状、大小、性质、理化行为、稳定性和宿主特异性进行调整。了解有关该核心平台技术的所有信息,以及如何利用合作增强的专业知识克服生产难题。

查看所有结果

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门